免責聲明
本網站僅提供窩客幫資訊參考平台, 並不涉入其中任何諮詢、交易。本網站對各該窩客幫相關資訊亦不作任何實質或形式上之審查。本網站中所載一切窩客幫的資訊、文字、照片、圖形 、產權、廣告內容、或其他資料(以下簡稱『內容』)。無論其為公開張貼或私下傳送,若有不實或違法情事,均為『內容』提供者之責任,窩客幫概不負責也不承擔任何法律責任。
豐華生物科技股份有限公司
文章管理
PRONULIFE® VagProtect
Designed for Intimate Wellness
PRONULIFE® VagProtect is a clinically supported multi-strain probiotic formulation specifically designed to support women’s intimate microbiome balance. It helps maintain a normal vaginal environment, making it suitable for daily intimate care and supporting the overall health of the vaginal microbiota.


The Science Behind Women’s Intimate Health
The vaginal ecosystem naturally harbors more than 50 species of microorganisms, with Lactobacillus species accounting for around 80%. These bacteria secrete acidic substances that help maintain a slightly acidic environment. When the immune system is challenged or intimate care is inadequate, vaginal pH may shift, disrupting the natural microbial balance.

Scientific studies indicate that probiotics, through the gut–vaginal axis, can modulate immune responses, support microbiome balance, and strengthen natural defenses.

Exclusive Multi-Strain Formula with Advanced Microencapsulation Technology
PRONULIFE® VagProtect contains four well-studied Lactobacillus strains:
Lactobacillus salivarius AP-32
Lactobacillus rhamnosus F-1
Lactobacillus rhamnosus CT-53
Lactobacillus reuteri TE-33

The formulation is protected by Glac’s patented PRONEX® microencapsulation technology, ensuring probiotic stability throughout storage and use.

Scientific Evidence & Regulatory Recognition
• Multiple studies demonstrate its ability to support intimate microbiome balance
• Research shows it helps maintain a normal vaginal environment
• Suitable as a nutritional supplement for daily intimate wellness
• Listed with the Australian Therapeutic Goods Administration (ARTG ID 329111), meeting international safety standards


 

Why Choose Glac Biotech as Your Probiotic Raw Material & ODM/OEM Partner?
Professional Advantages
Turnkey ODM/OEM Service – Full support from product development to regulatory compliance
Patented Formulations & Technology – Exclusive microencapsulation solutions to boost product competitiveness
Scientific Validation – Backed by extensive studies and publications
Customization – Flexible solutions tailored for different markets and client needs

Patents
• TWI 451871 – Probiotic composition patent
• TWI 542353 – Probiotic food composition patent
• CN102835657B – Probiotic composition patent (China)
• US9011839B2 – Probiotic composition patent (U.S.)



Start Your Intimate Wellness Journey with PRONULIFE® VagProtect

For more information, please contact us📧

Further Reading  PRONULIFE® Functional Probiotic Ingredients🔙
 


Science papers
  1. Comparative effect of viable and Heat-Killed Lactic acid Bacteria on immunomodulation. The 6th Asian Conference on Lactic Acid Bacteria. 2011. P-AM11-44. P52..
  2. Inhibition of in vitro growth of pathogens to protect human mucosa by probiotics. 2012. CIFST P2-18.
  3. Potential of probiotic strains to modulate the inflammatory responses of epithelial and immune cells in vitro. NEW MICROBIOLOGICA, 2013, P167-179.
  4. Defense of pathogen infection via modulation of tight junction protein by the probiotic strain L. salivarius ssp.salivarius AP-32. The 6th International Conference on Food  Factors. 2015. P-0482.
  5. Comparison of the inhibition effect of lactic acid bacteria fermentation metabolites on different vaginal pathogens and developing gynecological probiotic products. CIFST. 2017
  6. Inhibitory effects of viable and heat-killed lactic acid bacteria against different vaginal pathogens: toward development of gynecological probiotics. IUMS.2017
  7. Bacteriostatic activities of lactic acid bacteria against extended-spectrum β-lactamase(ESBL)-producing Escherichia coli. Basic Clin Pharmacol Toxicol. 2019;125(Suppl. 6):3-4.
  8. Bacteriostatic abilities of viable and heat-killed lactic acid bacteria against group B Streptococcus. Basic Clin Pharmacol Toxicol. 2019;125:12-13.
  9. Assessment of bacteriostatic activities of viable and non-viable lactic acid bacteria against methicillin-resistant Staphylococcus aureus. Basic Clin Pharmacol Toxicol. 2019;125:14-15.

 
相關文章
豐華生物科技股份有限公司
電話 : +886-6-589-1876 地址 : 1 F., No. 139, Sanmin St., Xinshi Dist., Tainan City 744007, Taiwan (R.O.C.) 信箱 : glac@glac.com.tw

  • 服務項目

  • 特別關鍵字